국가: 캐나다
언어: 영어
출처: Health Canada
ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE
PATRIOT A DIVISION OF JANSSEN INC
N02AJ13
TRAMADOL AND PARACETAMOL
325MG; 37.5MG
TABLET
ACETAMINOPHEN 325MG; TRAMADOL HYDROCHLORIDE 37.5MG
ORAL
60
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0250601001; AHFS:
CANCELLED POST MARKET
2014-11-11
_ _ _Page 1 of 40 _ PRODUCT MONOGRAPH PR PAT-TRAMADOL/ACET tramadol hydrochloride and acetaminophen tablets, USP 37.5 mg tramadol hydrochloride/325 mg acetaminophen Centrally Acting Analgesic Patriot, a division of Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.patriot-canada.ca Date of Preparation: July 9, 2012 Date of Revision: September 5, 2014 SUBMISSION CONTROL NO: 177222 © 2014 Patriot, a Division of Janssen Inc. _ _ _Page 2 of 40 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 10 DRUG ABUSE, ADDICTION AND DEPENDENCE ............................................................ 12 DRUG INTERACTIONS ......................................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................................... 14 OVERDOSAGE ....................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 17 STORAGE AND STABILITY ................................................................................................. 21 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 21 PART II: SCIENTIFIC INFORMATION ......................................... 전체 문서 읽기